Amgen (AMGN) Other Non-Current Liabilities (2009 - 2026)

Amgen's Other Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $2.8 billion for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 25.07% year-over-year to $2.8 billion; the TTM figure through Mar 2026 stood at $2.8 billion (up 25.07% YoY), while the FY2025 annual figure was $2.4 billion, up 1.23% from the prior year.
• Other Non-Current Liabilities was $2.8 billion for Q1 2026 at Amgen, up from $2.4 billion in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $6.7 billion in Q1 2022 to a low of $96.0 million in Q1 2024.
• Historically, Other Non-Current Liabilities has averaged $2.2 billion across 5 years, with a median of $2.2 billion in 2025.
• The sharpest annual moves came in 2023 and 2025: Other Non-Current Liabilities tumbled 96.59% in 2023, then jumped 2202.08% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $270.0 million in 2022, then soared by 1633.33% to $4.7 billion in 2023, then tumbled by 49.81% to $2.3 billion in 2024, then increased by 1.23% to $2.4 billion in 2025, then climbed by 16.23% to $2.8 billion in 2026.
• The last three Other Non-Current Liabilities figures came in at $2.8 billion (Q1 2026), $2.4 billion (Q4 2025), and $2.2 billion (Q3 2025), per Business Quant data.